2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1178

Educational Impact of a Clinical Anatomy Workshop on 1st-Year Orthopedic and Rheumatology Fellows and a Comparison of Scores Between Specialties in Mexico
Abstract Number: 1311

Effect of a Non Biologic Treat-to-Target Strategy on MRI-Determined Inflammatory and Destructive Changes in Early Rheumatoid Arthritis – Results from a 2-Year Investigator-Initiated Double-Blind Randomized Controlled Clinical Trial
Abstract Number: 2733

Effect of Abatacept on Telomerase Activity of Lymphocytes of Patients with Rheumatoid Arthritis
Abstract Number: 2039

Effect of Adalimumab on Visual Functioning (VFQ-25) in Visual-1 Trial Patients with Non-Anterior Non-Infectious Uveitis
Abstract Number: 3172

Effect of Anti Citrullinated Protein Antibodies on Periarticular and Systemic Bone Mass in Early Arthritis Patients
Abstract Number: 2668

Effect of Anti-Cyclic Citrullinated Peptide 2 Immunoglobulin M Serostatus on Efficacy Outcomes Following Treatment with Abatacept Plus Methotrexate
Abstract Number: 1576

Effect of Conventional Synthetic and Biological Disease Modifying Anti-Rheumatic Drugs on the Immunogenicity of Hepatitis B Vaccine in Patients with Rheumatoid Arthritis
Abstract Number: 1553

Effect of Drug Therapy on Net Cholesterol Efflux Capacity of HDL-Enriched Serum in Rheumatoid Arthritis
Abstract Number: 6L

Effect of Interleukin-17A Inhibition on Spinal Radiographic Changes through 2 Years in Patients with Active Ankylosing Spondylitis: Results of a Phase 3 Study with Secukinumab
Abstract Number: 1640

Effect of Methotrexate Dose on the Efficacy of Tofacitinib: Treatment Outcomes from a Phase 3 Clinical Trial of Patients with Rheumatoid Arthritis
Abstract Number: 1144

Effect of PEP-1-Glrx-1 on Catabolic Gene Expression in Human Articular Chondrocytes and in Mouse Carrageenan-Induced Paw Edema Model
Abstract Number: 2579

Effect of Tacrolimus on Endoplasmic Reticulum Stress-Mediated Osteoclastogenesis in a Collagen-Induced Arthritis Mouse Model
Abstract Number: 2919

Effect of Thrombotic Microangiopathy on Clinical Outcomes in LUPUS Nephritis
Abstract Number: 1537

Effect of TNF-Alpha Blockade on Body Composition in Inflammatory Rheumatic Disease: Systematic Review with Meta-Analysis
Abstract Number: 266

Effect of Tocilizumab on Adults Onset Still’s Disease in Korean Population: Multicenter Retrospecitve Study of 24 Cases

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].